TCR2 Therapeutics Inc. TCRR
1.48 0.00 (+0.00%)
At closeMay 31, 2023, 4:00 PM EDT
1.48 Day range 1.48
52-week range unavailable
News
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 9, 2023 
pennystocks.com 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% Penny stocks to buy according to analysts in 2023 The post 5 Penny Stocks To Buy According To Analysts, Targets Up To 952% appeared first on Penny Stocks to Buy, Picks, News and Information |…
benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For March 7, 2023 
investorplace.com Why Is TCR2 Therapeutics (TCRR) Stock Up 30% Today? TCR2 Therapeutics (NASDAQ: TCRR ) stock is jumping more than 30% in early trading on March 6 after the company agreed to merge with Adaptimmune (NASDAQ: ADAP ). Meanwhile, Adaptimmune is falling more…
seekingalpha.com TCR² Therapeutics: Refocused Pipeline Puts It On A Solid Path Reprioritization of pipeline sees 40% reduction of workforce with enough cash to fund pipeline into early 2025. Proof of concept established using gavo-cel for the treatment of patients with…
globenewswire.com TCR² Therapeutics to Present at SVB Securities Global Biopharma Conference 2023 CAMBRIDGE, Mass., Feb. 08, 2023 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…
benzinga.com Why Spruce Biosciences Shares Are Trading Higher By 100%? Here Are Other Stocks Moving In Friday's Mid-Day Session Gainers Swvl Holdings Corp. (NASDAQ: SWVL) surged 133% to $0.3218. Swvl recently announced the commencement of a strategic review process.- benzinga.com Benzinga's Top Ratings Upgrades, Downgrades For January 5, 2023
- benzinga.com Stocks That Hit 52-Week Lows On Thursday Thursday's session saw 329 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 298 companies achieved new lows for the year.
benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's trading, 293 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 241 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 115 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Monday Monday saw 196 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 127 companies set new 52-week lows.
globenewswire.com TCR² Therapeutics to Present at the Piper Sandler Healthcare Conference CAMBRIDGE, Mass., Nov. 23, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…
zacks.com Down 16.6% in 4 Weeks, Here's Why You Should You Buy the Dip in TCR2 Therapeutics Inc. (TCRR) TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…- benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 283 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday morning, 446 companies hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday On Wednesday, 200 companies hit new 52-week lows.
globenewswire.com TCR² Therapeutics to Announce Complete Phase 1 Portion of the Gavo-cel Phase 1/2 Clinical Trial for Mesothelin-Expressing Solid Tumors CAMBRIDGE, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…
globenewswire.com TCR² Therapeutics to Present at the Jefferies Cell & Genetic Medicine Summit CAMBRIDGE, Mass., Sept. 26, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…
benzinga.com Stocks That Hit 52-Week Lows On Monday Monday saw 825 companies set new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 1076 companies hit new 52-week lows.
seekingalpha.com TCR² Therapeutics: Betting On A Solid Reversal TCR² Therapeutics is a company developing two lead oncology drug candidates targeting mesothelin, a protein expressed on different tumors. Its lead candidate gavo-cel, or TC-210, has presented strong…
globenewswire.com TCR² Therapeutics to Participate in Two Upcoming Conferences in June CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…- benzinga.com Stocks That Hit 52-Week Lows On Thursday During Thursday, 849 stocks hit new 52-week lows.
benzinga.com Stocks That Hit 52-Week Lows On Wednesday Wednesday's session saw 784 companies set new 52-week lows.- benzinga.com Stocks That Hit 52-Week Lows On Tuesday On Tuesday, 242 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Monday On Monday, 671 companies achieved new lows for the year.
- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's trading, 505 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday On Friday, 313 companies hit new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 147 companies achieved new lows for the year.
globenewswire.com TCR² Therapeutics to Present at the SVB Leerink Global Healthcare Conference CAMBRIDGE, Mass., Feb. 09, 2022 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients…- benzinga.com Stocks That Hit 52-Week Lows On Wednesday During Wednesday's morning trading, 400 companies set new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Lows On Friday During Friday's session, 445 companies made new 52-week lows.
zacks.com Here's Why TCR2 Therapeutics Inc. (TCRR) is Poised for a Turnaround After Losing 20.2% in 4 Weeks TCR2 Therapeutics Inc. (TCRR) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising…
globenewswire.com TCR² Therapeutics to Present at the J.P. Morgan Healthcare Conference CAMBRIDGE, Mass., Jan. 07, 2022 (GLOBE NEWSWIRE) -- https://investors.tcr2.com/- benzinga.com Stocks That Hit 52-Week Lows On Thursday On Thursday, 615 stocks hit new 52-week lows.
globenewswire.com TCR² Therapeutics to Present at the H.C. Wainwright BioConnect Conference CAMBRIDGE, Mass., Jan. 05, 2022 (GLOBE NEWSWIRE) -- TCR² Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for cancer patients…
pulse2.com TCRR Stock: Why It Increased Today The stock price of TCR2 Therapeutics (Nasdaq: TCRR) increased by over 1% pre-market today. This is why it happened.
globenewswire.com TCR² Therapeutics to Host R&D Day on October 20, 2021 CAMBRIDGE, Mass., Oct. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…
pulse2.com TCRR Stock: Why It Significantly Decreased Today The stock price of TCR2 Therapeutics Inc (NASDAQ: TCRR) fell by over 30% during intraday trading. This is why it happened.
globenewswire.com TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid Tumors - Clinical activity observed in all three mesothelin-expressing tumor types treated
globenewswire.com TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid Tumors CAMBRIDGE, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…
globenewswire.com TCR² Therapeutics to Present at the H.C. Wainwright Global Investment Conference CAMBRIDGE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) -- TCR2 Therapeutics Inc. (Nasdaq: TCRR), a clinical-stage cell therapy company with a pipeline of novel T cell therapies for patients suffering from…- benzinga.com Stocks That Hit 52-Week Lows On Tuesday During Tuesday's morning session, 216 companies made new 52-week lows.
- benzinga.com Stocks That Hit 52-Week Highs On Monday Monday's morning session saw 240 companies set new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Tuesday Before 10 a.m. ET on Tuesday, 172 companies hit new 52-week highs.
- benzinga.com Stocks That Hit 52-Week Highs On Monday During the morning session on Monday, 243 stocks hit new 52-week highs.